No abstract

Background: Systemic Immune-inflammation Index (SII) has been shown to correlate with the prognosis of numerous malignancies, but researchers have not yet reached an agreed conclusion on bladder cancer. To fill the blank, we conducted a meta-analysis to assess the prognostic role of SII in the prognosis of bladder cancer.Methods: After analyzing relevant literature published in PubMed, China National Knowledge Infrastructure, EMBASE, Cochrane Library, and Web Science up to April 30, 2022, we collected 83 articles to assess the significance of SII levels in assessing the prognosis of bladder cancer patients, and finally, 11 articles were included in the study. The correlation between pre-treatment Systemic Immunoinflammatory Index levels and survival in bladder cancer patients was assessed using risk ratio (HR) and 95% confidence interval (CI).Results: Our meta-analysis comprised 11 papers altogether, and the findings revealed that higher levels of pretreatment SII were significantly associated with poorer overall survival/cancer-specific survival/progression-free survival/recurrence-free survival in bladder cancer patients (pooled HR = 1.80; 95% CI, 1.28-2.51; pooled HR = 1.68; 95% CI, 1.14-2.47; pooled HR = 1.74; 95% CI, 1.25-2.42; pooled HR = 1.73; 95% CI, 1.26-2.39). The above result was also confirmed in the subgroup analysis.Conclusions: Higher SII levels were significantly connected with overall survival/cancer-specific survival/progression-free survival/recurrence-free survival rates in bladder cancer patients, suggesting that SII is an important predictor of prognosis in bladder cancer patients.

Background: The pretreatment prognostic nutritional index (PNI) is an indicator of nutritional and immune status, and has potential use as a predictor of survival in cancer patients. Several retrospective studies have used the PNI to predict the outcome of lung cancer patients receiving different immune checkpoint inhibitors (ICIs), but the results have been inconsistent. The objective of our study is to assess the relationship of pretreatment PNI with survival outcomes in lung cancer patients who received ICIbased treatments by meta-analysis.Methods: We searched the EMBASE, PubMed, Cochrane Library, American Society of Clinical Oncology, and European Society of Medical Oncology databases to identify studies that reported overall survival (OS) or progression-free survival (PFS) in eligible patients. Eight studies were eligible based on predefined inclusion and exclusion criteria. Data and pooled indicators were extracted from these studies. Meta-analysis was used to analyze hazard ratios (HRs) and 95% confidence intervals (CIs) for OS and/or PFS and the prognostic value of pretreatment PNI. We completed the registration of the research protocol (Registration number: INPLASY202240087,

Background: Premature ovarian insufficiency (POI) is the loss of function of the ovaries before age 40. Chinese herbal medicine (CHM) has been treating POI for long time. Therefore, we conduct this study to assess the efficacy and safety of CHM for POI. Methods: Seven databases will be searched from inception to December 31, 2018: PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), China Biology Medicine disc (CBM), WanFang Database, and Chongqing Chinese Scientific Journal Database (CQVIP). Randomized controlled trials that used CHM will be included. Two reviewers will independently complete the study selection, data extraction, and study quality assessment according to Cochrane Collaboration. All the data will be analyzed using Review Manage 5.3 software. Results: This study will generate a comprehensive summary on effectiveness and safety of CHM for POI. Conclusion: This study may be beneficial to health policymakers, clinicians, and patients with regard to the use of CHM in POI treatment. Trial registration number: PROSPERO CRD 42019144629.

Purpose: To demonstrate the prognostic value of pretreatment red blood cell distribution width (RDW) in patients with urological cancer. Methods: We searched the relevant literature on Web of Science, Cochrane Central Register of Controlled Trials, PubMed, Embase, Sinomed databases and Chinese National Knowledge Infrastructure up to 30 March 2022, to investigate the relationship between RDW levels and the prognosis of patients with urological tumors. Results: This study comprised 15 retrospective studies involving 9492 patients. Increased pretreatment RDW was associated with poorer overall survival (hazard ratio [HR]: 1.52; 95% CI: 1.27–1.82; p < 0.001), cancer-specific survival (HR: 1.34; 95% CI: 1.15–1.57; p < 0.001) and progression-free survival (HR: 1.53; 95% CI: 1.26–1.86; p < 0.001). Conclusion: High pretreatment RDW might predict poor survival for patients with urologic cancers.

Background and objective: In modern clinical medicine, the most prevalent category of cancer is lung cancer, and the brain is a routine organ of metastasis for lung cancer. Recently, researchers have evaluated hematologic indicators such as neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) and confirmed that they are valid indices for predicting outcome of lung cancer patients. However, the prognostic significance for lung cancer patients who have progressed to brain metastasis has not been clarified. In our study, a meta-analysis which focus on the association of pre-treatment NLR, PLR and overall survival (OS) in lung cancer patients with brain metastasis was performed and reported. Methods PubMed, Embase and CNKI databases were the scope of our search, and the search methodology was derived from PRISMA. Meta-analyses of OS were performed using random effects models due to significant heterogeneity. This study has been registered on PROSPERO (CRD42022329590). Results We finally included 11 articles to evaluate NLR and PLR in 1977 eligible patients. The NLR group consisted of 11 studies whose meta-analysis showed that OS was significantly shorter in high-NLR patients than low-NLR patients (pooled HR = 1.84 (95% CI: 1.47–2.31)). Five studies were included in the PLR group, and the result suggested that OS was significantly shorter in high-PLR patients than low-PLR patients (pooled HR = 1.53 (95% CI: 1.07–2.20)). Conclusions Meta-analysis showed that association of pre-treatment NLR, PLR and OS are statistically significant. Pre-treatment lower NLR and PLR predict better OS.

Background: Whether the size of thymic epithelial tumors (TETs) has an impact on prognosis has long been a controversial issue. Our study was designed to investigate the value of tumor size in the prognosis (overall survival (OS) and relapse-free survival) of patients with TETs. Methods: We searched the databases such as PubMed, EMBASE, Web of Science, and clinical trials registration system for articles illustrating the impact of tumor size on survival data in TETs patients. We did a meta-analysis for OS and relapse-free survival. Results: We recruited 9 studies in our meta-analysis. Our study illustrates that TETs patients with small tumor size had better relapse-free survival (hazard ratio = 1.66, 95% confidence interval 1.18–2.35, P = .004) and OS (hazard ratio = 1.93, 95% confidence interval 1.30–2.80, P = .001) in comparison to patients with large tumor size. Conclusions: In conclusion, the results of our meta-analysis showed that TET size was significantly associated with overall and relapse-free survival of patients, with relatively small tumors tending to have a better prognosis.

IntroductionAccording to the principle, thymomas combined with myasthenia gravis (MG) require surgical treatment. However, patients with non-MG thymoma rarely develop MG and early- or late-onset MG after surgery is called postoperative MG (PMG). Our study used a meta-analysis to examine the incidence of PMG and risk factors.MethodsRelevant studies were searched for in the PubMed, EMBASE, Web of Science, CNKI,and Wanfang databases. Investigations that directly or indirectly analyzed the risk factors for PMG development in patients with non-MG thymoma were included in this study. Furthermore, risk ratios (RR) with 95% confidence intervals (CI) were pooled using meta-analysis, and fixed-effects or random-effects models were used depending on the heterogeneity of the included studies.ResultsThirteen cohorts containing 2,448 patients that met the inclusion criteria were included. Metaanalysis revealed that the incidence of PMG in preoperative patients with non-MG thymoma was 8%. Preoperative seropositive acetylcholine receptor antibody (AChR-Ab) (RR = 5.53, 95% CI 2.36 – 12.96, P&lt;0.001), open thymectomy (RR =1.84, 95% CI 1.39 – 2.43, P&lt;0.001), non-R0 resection (RR = 1.87, 95% CI 1.36 – 2.54, P&lt;0.001), world health organization (WHO) type B (RR =1.80, 95% CI 1.07 – 3.04, P= 0.028), and postoperative inflammation (RR = 1.63, 95% CI 1.26 – 2.12, P&lt;0.001) were the risk factors for PMG in patients with thymoma. Masaoka stage (P = 0.151) and sex (P = 0.777) were not significantly associated with PMG.DiscussionPatients with thymoma but without MG had a high probability of developing PMG. Although the incidence of PMG was very low, thymectomy could not completely prevent the occurrence of MG. Preoperative seropositive AChR-Ab level, open thymectomy, non-R0 resection, WHO type B, and postoperative inflammation were risk factors for PMG.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022360002.